Breast Cancer

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

Results of a phase 2 study showed that women with small, stage 1 HER2-positive breast cancer who received a combination of lower-intensity chemotherapy and Herceptin following surgery were highly unlikely to have a recurrence.

When was your last truly remarkable New Year's Eve?

The mental challenges of having stage 4 breast cancer are just as overwhelming as the physical ones.

The mental noise that comes with cancer is deafening. Taking cancer time-outs can quiet your anxiety.

Two HER2-targeting regimens anchored by Kadcyla (T-DM1) failed to outperform the standard strategy of Herceptin plus chemotherapy in women newly diagnosed with advanced HER2-positive breast cancer.

The addition of Avastin (bevacizumab) to standard neoadjuvant chemotherapy significantly improved pathologic complete response rates in women with basal-like breast cancer compared with non-basal-like subtypes.

Faslodex (fulvestrant) improved overall survival by nearly six months compared with anastrozole as initial hormone therapy for postmenopausal women with estrogen receptor-positive advanced breast cancer, according to findings from the phase 2 FIRST trial.

Dr. Mary Claire King's search for the breast cancer gene spanned 20 years.

Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54 percent when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.

Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.

Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.

Karen Durham never expected to be speaking on behalf of the Metastatic Breast Cancer Alliance

The PD-1 inhibitor Keytruda (pembrolizumab) has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer (TNBC).

When 34-year-old Jen Levinson was diagnosed with stage 2 breast cancer in 2000, the breast cancer world gained a powerful advocate -- but it wasn't Jen, it was her mother.

Debu Tripathy, editor-in-chief of CURE magazine, recaps the first day of the San Antonio Breast Cancer Symposium - namely the advances in treating breast cancer with immunotherapy.

Abraxane (nab-paclitaxel) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk, early breast cancer, according to results presented at the 2014 San Antonio Breast Cancer Symposium.

Andrea Ivory had an epiphany shortly after being diagnosed with breast cancer in 2004 at age 45.

The annual meeting of the European Society for Medical Oncology (ESMO) was held in September to discuss the latest data on critical issues in cancer treatment, diagnostics, prevention, supportive care and more.

Women with breast cancer who practice yoga during radiation treatment receive a number of benefits that appear to have long-term durability.

A recent survey reveals that most women aren't aware of the association between dense breast tissue and breast cancer risk.

Given the mixed messages involved, it's not surprising that women with ductal carcinoma in situ can become anxious and sometimes unduly alarmed by the diagnosis.

Susan Hope Schaffer, the 2014 Oncology on Canvas overall winner, shares how her experience with breast cancer helped her evolve as an artist.

Being a parent affects EVERY decision in my life, even the ones regarding my cancer care.

Breast cancer is a complicated family of diseases – the goal is personalized medicine, and a team-based approach should be the standard of care.

Lobular carcinoma in situ, or LCIS, is considered a risk factor for invasive cancer. 

The condition can be managed, and new treatments are being investigated.

Will suspicious cells remain idle or become aggressive breast cancers?

The NCNN recommends testing for Lynch syndrome for at-risk individuals, regardless of whether they have colorectal cancer.

Written by a husband who supported his wife through her illness, Husband’s Guide to Breast Cancer offers a straightforward game plan to guide men in their role as caregiver.